Evidence map›Paper›PMID 31647829›Full record

ArticlePloS one2019

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.

Katarzyna Kapica-Topczewska, Joanna Tarasiuk, Francois Collin, Waldemar Brola, Monika Chorąży, Agata Czarnowska, Mirosław Kwaśniewski, Halina Bartosik-Psujek, Monika Adamczyk-Sowa, Jan Kochanowicz and 1 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Katarzyna Kapica-TopczewskaDepartment of Neurology, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0002-9720-3204
Joanna TarasiukDepartment of Neurology, Medical University of Bialystok, Bialystok, Poland.
Francois CollinCentre for Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0003-0524-5755
Waldemar BrolaThe Faculty of Medicine and Health Sciences, Institute of Physiotherapy, Jan Kochanowski University, Kielce, Poland.ORCID 0000-0002-7955-3454
Monika ChorążyDepartment of Neurology, Medical University of Bialystok, Bialystok, Poland.
Agata CzarnowskaDepartment of Neurology, Medical University of Bialystok, Bialystok, Poland.
Mirosław KwaśniewskiCentre for Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland.
Halina Bartosik-PsujekNeurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Medical Faculty, University of Rzeszow, Rzeszów, Poland.
Monika Adamczyk-SowaDepartment of Neurology in Zabrze, Medical University of Silesia, Zabrze, Poland.
Jan KochanowiczDepartment of Neurology, Medical University of Bialystok, Bialystok, Poland.
Alina KułakowskaDepartment of Neurology, Medical University of Bialystok, Bialystok, Poland.
Medical University of Białystok · PLJan Kochanowski University · PLMedical University of Silesia · PLUniversity of Rzeszów · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the study was to assess the effectiveness of disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients treated in MS centres in Poland.

methodsDemographic and clinical data of all Polish RRMS patients receiving DMTs were prospectively collected from 2014 to 2018 in electronic files using the Therapeutic Program Monitoring System (SMPT).

resultsThe study included 10,764 RRMS patients treated with DMTs in first-line and 1,042 in second-line programmes. IFNβ more effectively lengthened the times to the first relapse, disability progression, and brain MRI activity than GA. After 2 and 4 years of follow-up, more patients on IFNβ showed no evidence of disease activity (NEDA-3) in comparison to GA (66.3% and 44.3% vs 55.2% and 33.2%, respectively; p<0.001). NAT more effectively reduced brain MRI activity than FTY (p = 0.001). More patients under NAT had NEDA-3 after 2 and 4 years of follow-up compared to FTY (66.2% and 42.1% vs 52.1% and 29.5%, respectively; p = 0.03). In adjusted analysis, a higher baseline Expanded Disability Status Score (EDSS) was a predictor of relapse (p<0.001) and NEDA-3 failure (p = 0.003).

conclusionIFNβ compared to GA and NAT compared to FTY more effectively reduced disease activity in a Polish population of RRMS patients.

Indexed as

AdultDrug Therapy, CombinationFemaleFingolimod HydrochlorideFollow-Up StudiesGlatiramer AcetateHumansImmunologic FactorsImmunosuppressive AgentsInterferon-betaMaleMultiple Sclerosis, Relapsing-RemittingNatalizumabPolandPrognosisProspective StudiesFingolimod HydrochlorideGlatiramer AcetateImmunologic FactorsImmunosuppressive AgentsInterferon-betaNatalizumab

Identifiers

PMID31647829
PMCPMC6812766
OpenAlexW2981436111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.